Clinical Research Directory
Browse clinical research sites, groups, and studies.
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Sponsor: Kupando GmbH
Summary
The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2026-07-03
Completion Date
2028-12
Last Updated
2026-11-18
Healthy Volunteers
No
Conditions
Interventions
KUP-101A
Intravenous infusion of KUP-101A
Locations (4)
Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie
Munich, Bavaria, Germany
Universitätsklinikum Würzburg
Würzburg, Bavaria, Germany
Universitätsklinikum Gießen und Marburg, Standort Marburg, Klinik für Dermatologie und Allergologie
Marburg, Hesse, Germany
Fachklinik Hornheide
Münster, North Rhine-Westphalia, Germany